News Valerio Therapeutics Börse Stuttgart

Stocks

C4X

FR0010095596

Pharmaceuticals

Real-time Estimate Tradegate 14:10:03 2026-09-18 EDT			5-day change	1st Jan Change
0.5830 ^EUR	-6.57%		-11.36%	-

08-24	Valerio Therapeutics to Buy Etherna Immunotherapies in EUR30 Million Deal	MT
08-17	Valerio Therapeutics Nears Final Deal for Etherna Immunotherapies Purchase	MT

All News

Mentions Relevance

08-24	Valerio Therapeutics to Buy Etherna Immunotherapies in EUR30 Million Deal	MT
08-24	Valerio Therapeutics : Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors	PU
08-24	Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors	BU
08-17	Valerio Therapeutics Nears Final Deal for Etherna Immunotherapies Purchase	MT
08-17	Valerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated Acquisition	BU
07-16	Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update	BU
07-16	Valerio Therapeutics : Announces Development Collaboration with Abivax and Provides Pipeline Update	PU
07-01	Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines	BU
07-01	Valerio Therapeutics : announces binding offer for the proposed acquisition of Etherna Immunotherapies, creating a global leader in targeted RNA medicines	PU
06-30	Valerio Therapeutics Société anonyme signed a letter of intent to acquire eTheRNA immunotherapies NV for an enterprise value of ?30 million.	CI
06-17	Valerio Therapeutics Appoints New Chief Executive Officer
06-17	Valerio Therapeutics Names New CEO	MT
06-16	Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting	BU
06-16	Valerio Therapeutics Société Anonyme Announces Board and Executive Changes	CI
06-16	Valerio Therapeutics Société Anonyme Announces CEO Changes	CI
06-16	Valerio Therapeutics : Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting	PU
05-19	Valerio Therapeutics Signs Binding Term-sheet for V-Body Platform Collaboration	MT
05-18	Valerio Therapeutics enters into collaboration & exclusive license with seed-stage biotech co	RE
05-18	Valerio Therapeutics Announces Binding Term-Sheet for Collaboration and Exclusive License With Seed-Stage Biotech Company	BU
05-18	Valerio Therapeutics Enters Binding Term-Sheet for Collaboration and Exclusive License with Stealth-Mode Biotech Company	CI
05-18	Valerio Therapeutics : announces binding term-sheet for collaboration and exclusive license with seed-stage biotech company	PU
05-04	Valerio Therapeutics : Inside Information / Other news releases	PU
05-04	Valerio Therapeutics Announces Launch of Invimmune and Provides Update on in Vivo Cell Therapy Approaches	CI
05-04	Valerio Therapeutics Launches New Company for In Vivo Cell Therapies	MT
05-04	Valerio Therapeutics Announces the Launch of InVimmune, a New Company Dedicated to Developing Differentiated in Vivo Cell Therapy Approaches	BU